Ultragenyx Pharmaceutical Inc. Overview
Pro stress-test →Ultragenyx is a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need for which there are typically no approved therapies treating the underlying disease.
Strategic Profile
Pro stress-test →Ultragenyx's strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency. The company's advancing late-stage pipeline, successful product launches, and gene therapy innovation position it for diversified growth and improved profitability.
Competitive Landscape
Pro stress-test →Ultragenyx is covered by 34 analysts, with 18 submitting estimates used in coverage reports. The company competes in the rare disease therapeutic space with other biotech firms developing treatments for genetic metabolic disorders, lysosomal storage diseases, and neurological conditions. Heavy reliance on a limited product portfolio and potential biosimilar competition threaten long-term revenue growth and margin expansion.
Industry Context
Ultragenyx Pharmaceutical Inc. operates in Biopharmaceutical - Rare and Ultra-Rare Genetic Disease Therapeutics.
Key facts
Founded: 2010 · Headquarters: Novato, CA, USA · Revenue: $670M · Market cap: $2.27B